AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34656955
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg MOFs
Trial: 34332956
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg bolus then 0.12 mg/kg/h infusion for the first 24 hours postoperative
Trial: 34332956
Drug: Ketamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.5 mg/kg and Mg sulfate 50 mg/kg, then ketamine 0.12 mg/kg/h and Mg sulfate 8 mg/kg/h infusions for the first 24 hours postoperative
Trial: 34428440
Drug: Text message-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message-based support (4 texts per week for 6 months) covering diet, physical activity, smoking, general cardiovascular health, and medication adherence.
Trial: 34264865
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg oral methylphenidate
Trial: 34653245
Drug: OVX836 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OVX836 (30 µg, 90 µg, or 180 µg)
Trial: 32331244
Drug: Standard antenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antenatal GDM management (insulin/metformin)
Trial: 34403046
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects on pH
Trial: 33270066
Drug: Thommen Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thommen Implant System
Trial: 36257846
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no supplemental treatment)
Trial: 32039724
Drug: Metformin (1700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1700 and 2000 mg/d)
Trial: 32039724
Drug: Metformin exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin exposure
Trial: 36351721
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of human-derived neural stem cells (hNSCs) for 4 consecutive weeks
Trial: 35737872
Drug: 5% sodium
RxNorm normalized name: Dextrose 5% and 0.45% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sodium fluoride (NaF) varnish with standard oral hygiene instructions (OHI)
Trial: 35737872
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral hygiene instructions (OHI)
Trial: 34261354
Drug: Inoculation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculation with 20 μl of 10^6 conidia/ml suspensions of C. fioriniae and C. nymphaeae isolates
Trial: 33444189
Drug: Gluten-free diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten-free diet (GFD) including at least 6 gluten-free breads per day + 200g of gluten-free penne pasta per week + 6 rice flavour capsules per day
Trial: 33444189
Drug: Gluten-containing diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten-containing diet including at least 6 gluten-containing breads per day + 200g of gluten-containing penne pasta per week + 6 vital gluten-containing capsules per day
Trial: 36170749
Drug: mART (maternal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mART (maternal antiretroviral therapy)
Trial: 36408821
Drug: Multiple oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple oral doses of HR20033
Trial: 35681162
Drug: Stratified exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified exercise therapy (including dietary intervention for the 'obesity subgroup')
Trial: 35681162
Drug: Stratified exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified exercise therapy (for the 'obesity subgroup')
Trial: 35681162
Drug: Stratified exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified exercise therapy (for the 'high muscle strength subgroup')
Trial: 35681162
Drug: General knee
RxNorm normalized name: Bos taurus knee joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General knee OA treatment
Trial: 33098189
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with less than 20% decline in 3-IGI PRO score after two treatment cycles
Trial: 32513226
Drug: Intensive face-to-face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive face-to-face sessions (mean dose delivered 10.9 of 12 sessions)
Trial: 32513226
Drug: Maintenance phone
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance phone calls (mean dose delivered 7.7 of 9 calls)
Trial: 32513226
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intensive sessions (>6) and maintenance calls (>8)
Trial: 32513226
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (zero dose)
Trial: 38606412
Drug: Learning Through
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Learning Through Play plus Culturally adapted Cognitive Behaviour Therapy (LTP+CaCBT)
Trial: 33358255
Drug: Long-term cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term cilostazol treatment
Trial: 33358255
Drug: High high-sensitivity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High high-sensitivity chronic reactive protein level, diabetic neuropathy, sole use of an oral hypoglycemic agent, and lack of supervised exercise
Trial: 33721199
Drug: 80 IU
RxNorm normalized name: Ascorbic Acid/Garlic/Vitamin A/Vitamin E 160 MG-300 MG-5280 IU-40 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 IU intranasal insulin
Trial: 34071485
Drug: Enriched yogurt
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enriched yogurt with PAF inhibitors from olive pomace
Trial: 35774049
Drug: Standard optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard optimal medical therapy (OMT)
Trial: 32959589
Drug: Preoperative acupoint
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative acupoint application therapy
Trial: 32959589
Drug: Postoperative acupoint
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative acupoint application therapy